The present invention provides new compounds with high affinity for adenosineA 2A receptors. It also provides antagonistsof adenosine A 2A receptors and their use as medicaments for the treatmentand/or prophylaxis of diseases and disorderswhere the partial or total inactivation of adenosine A 2A receptors signallingpathways could be beneficial such as Alzheimer's disease,Parkinson's disease, attention deficit and hyperactivity disorders (ADHD),Huntington's disease, neuroprotection,schizophrenia, anxiety and pain. The present invention further relates topharmaceutical compositions containing such new compoundswith high affinity for adenosine A 2A receptors and their use for thetreatment and/or prophylaxis of diseases and disorderswhere the partial or total inactivation of adenosine A 2A receptors could bebeneficial.
